Largest drug divestiture order in FTC pharma merger caseStaff Writer | July 28, 2016
Teva Pharmaceutical Industries has agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges.
Selling FTC requires Teva to divest over 75 generic drugs
The remedy requires Teva to divest the drug portfolio to eleven firms, and marks the largest drug divestiture order in an FTC pharmaceutical merger case.
The FTC order will preserve competition in U.S. pharmaceutical markets where Teva and Allergan compete now or would likely have competed in the future if not for the merger.
The divested products include anesthetics, antibiotics, weight loss drugs, oral contraceptives, and treatments for a wide variety of diseases and conditions, including ADHD, allergies, arthritis, cancers, diabetes, high blood pressure, high cholesterol, mental illnesses, opioid dependence, pain, Parkinson’s disease, and respiratory, skin and sleep disorders.
As explained in its Statement, the Commission also evaluated whether this transaction would have anticompetitive effects beyond those occurring in individual product markets, but concluded that the evidence showed it was unlikely to do so.
Specifically, the Commission considered whether the transaction would lower incentives to develop or bring new generic drugs to market, as well as whether the combined company’s ability to bundle products could have an anticompetitive effect.
The acquirers of the divested products are Mayne Pharma Group Ltd., Impax Laboratories, Inc., Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited, Zydus Worldwide DMCC, Mikah Pharma LLC, Perrigo Pharma International D.A.C., Aurobindo Pharma USA, Inc., Prasco LLC and 3M Company.
Teva and Allergan must divest the drug products no later than 10 days after the acquisition is complete, and to help ensure that the order achieves its remedial goals, they are required to provide technical assistance and other transitional services to ensure that the acquirers can independently manufacture and sell the divested products.
The FTC order includes an asset maintenance order and enables the Commission to appoint two interim monitors.
In addition to the product divestitures, to address the anticompetitive effects likely to arise in markets for 15 pharmaceutical products where Teva supplies active pharmaceutical ingredients to current or future Allergan competitors, the FTC order additionally requires Teva to offer these existing API customers the option of entering into long-term API supply contracts.
This option ensures that these customers have access to essential API inputs and provides them sufficient time to qualify alternative suppliers if they choose to do so. ■